Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 1Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 62Breast Neoplasms 44Prostatic Neoplasms 35Lung Neoplasms 29Multiple Myeloma 24Neoplasms 22Colorectal Neoplasms 19Parkinson Disease 4, Autosomal Dominant Lewy Body 18Ovarian Neoplasms 17Neoplasm Metastasis 17Leukemia, Lymphocytic, Chronic, B-Cell 17Carcinoma, Renal Cell 15Pancreatic Neoplasms 13Small Cell Lung Carcinoma 12Endometrial Neoplasms 12Urinary Bladder Neoplasms 10Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Leukemia, Myeloid, Acute 10Myasthenia Gravis 9Lymphoma, Follicular 9Fallopian Tube Neoplasms 9Non-Muscle Invasive Bladder Neoplasms 8Colonic Neoplasms 8Recurrence 7Burkitt Lymphoma 7Lymphoma, Mantle-Cell 6Esophageal Neoplasms 6Carcinoma 6Biliary Tract Neoplasms 6

Interventions

cabozantinib 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphatic Metastasis × 30 days × Clear all
NCT03793166 2026-05-29

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,175 enrolled
Genitourinary

Carcinoma, Renal Cell, Lymphatic Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡